|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1981
|
|
gptkbp:atc_code
|
A02 BA02
|
|
gptkbp:available_on
|
gptkb:tablet
gptkb:Sugar
injection
|
|
gptkbp:brand
|
gptkb:Zantac_150
gptkb:Zantac_75
|
|
gptkbp:casnumber
|
66357-35-5
|
|
gptkbp:chemical_formula
|
C13 H9 N5 O2
|
|
gptkbp:class
|
H2 antagonist
|
|
gptkbp:condition
|
peptic ulcer disease
esophagitis
dyspepsia
|
|
gptkbp:contraindication
|
porphyria
hypersensitivity to ranitidine
|
|
gptkbp:financial_support
|
do not exceed recommended dose
consult doctor before use in breastfeeding
consult doctor before use in pregnancy
discontinue if allergic reaction occurs
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zantac
|
|
gptkbp:ingredients
|
gptkb:ranitidine
|
|
gptkbp:interacts_with
|
gptkb:itraconazole
gptkb:ketoconazole
gptkb:procainamide
gptkb:theophylline
gptkb:warfarin
|
|
gptkbp:legal_status
|
over-the-counter
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:pharmacokinetics
|
excreted in urine
metabolized in liver
bioavailability 50%
half-life 2-3 hours
|
|
gptkbp:reason_for_withdrawal
|
concerns over NDMA contamination
|
|
gptkbp:replaces
|
gptkb:2019
|
|
gptkbp:route_of_administration
|
oral
intravenous
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
diarrhea
constipation
|
|
gptkbp:used_for
|
treating gastroesophageal reflux disease (GERD)
treating Zollinger-Ellison syndrome
treating heartburn
|
|
gptkbp:weight
|
314.34 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Pfizer_Consumer_Healthcare
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:bfsLayer
|
5
|